Table 7.
Cannabinoids
| Study | Investigated Drug (N) | Sample | Opioid | Pain Outcomes | Duration | Findings |
|---|---|---|---|---|---|---|
| Narang et al, 2008 | 1ST phase: Dronabinol (10, 20 mg PO) (N=30) 2nd phase: Dronabinol 5-60mg per day |
Individuals with chronic pain and opioid dependence (> 6 months). | Various opioid analgesics (e.g., oxycodone, hydrocodone) | Pain intensity (VAS) prior to and relief for 8hr post-treatment. | 1ST phasea: 2nd phaseb: 4 weeks. |
1ST phase: both 10 and 20 mg of dronabinol groups showed a small magnitude reduction in pain scores compared to the placebo. 2nd phase: modest reduction in mean pain intensity ratings. |
PO: Per oral/Orally.
a
1ST phase: randomized, crossover, placebo-controlled study.
b
2nd phase: open-label extension of 1ST phase.